CEO Interview: Canfite's Namodenoson and Its Impact on Cancer Treatment
Aug. 5, 2024
Can-Fite BioPharma (NYSE American: CANF) is focused on developing small molecule drugs targeting the A3 adenosine receptor (A3AR), a unique approach in treating pathological conditions including cancer and inflammatory diseases. The Company’s robust pipeline includes advanced-stage clinical candidates demonstrating promising efficacy and safety profiles for psoriasis and liver disease.
Strategically positioned with multiple out-licensing deals and potential milestone payments totaling over $130 million, Can-Fite has already received $20 million in upfront and milestone payments, underscoring the potential of its therapies. The Company has secured Fast Track and Orphan Drug designations from the FDA and EMA for its liver disease candidate, enhancing its regulatory pathway.
With advanced-stage assets targeting unmet medical needs in markets with a combined value in excess of $70 billion, Can-Fite is well positioned for the potential commercialization of its innovative therapies and has buy ratings from HC Wainwright and Alliance Global Partners with a median price target of $15 per share.
